Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

An intervention trial to inhibit the progression of precancerous gastric lesions: compliance, serum micronutrients and S-allyl cysteine levels, and toxicity

You, W C1; Chang, Y S2; Heinrich, J3; Ma, J L2; Liu, WD4; Zhang, L2; Brown, L M1; Yang, C S5; Gail, M H1; Fraumeni, J F Jr1; Xu, G W2

European Journal of Cancer Prevention: June 2001 - Volume 10 - Issue 3 - p 257-263
Research Papers

Gastric cancer is the second most frequent cause of death from cancer in the world and the leading cause of death from cancer in China. In September 1995, we launched a randomized multi-intervention trial to inhibit the progression of precancerous gastric lesions in Linqu County, Shandong Province, an area of China with one of the world's highest rates of gastric cancer. Treatment compliance was measured by pill counts and quarterly serum concentrations of vitamin C, vitamin E and S-allyl cysteine. In 1999, toxicity information was collected from each trial participant to evaluate treatment-related side-effects during the trial. Compliance rates were 93% and 92.9% for 39 months of treatment with the vitamins/mineral and garlic preparation, respectively. The means for serum concentrations of vitamins C and E were 7.2 μg/ml and 1695 μg/dl among subjects in the active treatment groups compared with 3.1 μg/ml and 752 μg/dl among subjects in the placebo treatment group, respectively. No significant differences in side-effects were observed between the placebo treatment group and the vitamins/mineral and garlic preparation treatment groups during the 39-month trial period.

1National Cancer Institute, Division of Cancer Epidemiology and Genetics, National Cancer Institute, EPS Room 8030, Bethesda, MD 20892, USA. 2Beijing Institute for Cancer Research and School of Oncology, Peking University, Beijing 100034, China. 3Westat, Rockville, MD 20850, USA. 4Linqu Public Health Bureau, Linqu, Shandong 262600, China. 5Rutgers University, Piscataway NJ 08855, USA

Correspondence to: W C You. Fax: (+1) 301 402 0081. E-mail:

Received 2 December 2000

Accepted 27 January 2001

© 2001 Lippincott Williams & Wilkins, Inc.